Skip to content

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05861063
Enrollment
105
Registered
2023-05-16
Start date
2023-02-11
Completion date
2024-12-31
Last updated
2023-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Atrophica

Keywords

Acne Scar, Dezocine, Pain Relief, Fractional CO2 Laser

Brief summary

The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser

Interventions

DEVICEFractional CO2 laser

All patients were given oral administration of 0.5mg paronosetron hydrochloride and lidocaine cream 1 hour before surgery. After cleaning and disinfection, fractional CO2 laser treatment was given. Among them, the fractional CO2 laser laser (American Medical Laser company) selected relatively constant energy parameters in the treatment

Desocine injection was injected intravenously half an hour before surgery (10ml normal saline was added for more than 30 seconds)

Sponsors

Xijing Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18-60 years old, regardless of gender; 2. Clinical diagnosis of atrophic acne scars; 3. Planning to undergo ultra-pulsed CO2 lattice laser therapy; 4. The patient agrees to participate in this experiment and signs an informed consent form

Exclusion criteria

1. Those who take sedative drugs for a long time; 2. Patients with sleep apnea syndrome, previous history of hypertension, and blood pressure greater than 160/100mmHg 3. People with severe heart and lung diseases, liver and kidney diseases, psychosis, pregnancy, and communication disorders; 4. Persons who are known to be allergic to the main drug or any of the excipients in Dezocine injection; 5. Increased intracranial pressure or head injury; 6. Acute and chronic alcoholism; 7. People with hypotension, hypothyroidism, acute episodes of asthma, and epilepsy \-

Design outcomes

Primary

MeasureTime frameDescription
Visual Analog Score for Pain24 hours0 was classified as painless and 10 was classified as unbearable pain. Marks were made on the corresponding parts of the ruler and scores were scored according to the degree of patient's feeling
Hemodynamic parameters24 hoursdiastolic blood pressure (DBP), systolic blood pressure (SBP)
Heart rate (HR)24 hoursHemodynamic parameters
oxygen saturation (SpO2)24 hoursHemodynamic parameters

Secondary

MeasureTime frameDescription
Occurrence of Adverse Reactions24 hoursNausea, vomiting,dizziness,respiratory depression

Countries

China

Contacts

Primary ContactChen Yu, MD
ycyc_2005@163.com13571991903

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026